Inovio announces online preprint publication of homologous boosting data for its covid-19 dna vaccine candidate, ino-4800

Plymouth meeting, pa., oct. 12, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced the online preprint publication in medrxiv of phase 1 clinical data on homologous boosting of its covid-19 dna vaccine candidate, ino-4800.
INO Ratings Summary
INO Quant Ranking